NuPathe, Inc. (PATH)
-NasdaqGM | Prev Close: | 3.11 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 6.50 |
|---|
| Beta: | 3.45 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.47 - 4.59 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 155,029 |
|---|
| Market Cap: | 90.41M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.73 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NUPATHE INC. FinancialsEDGAR Online Financials(Fri, May 17)
- NuPathe Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 14)
- NuPathe Announces First Quarter 2013 Financial Results and Operational HighlightsMarketwired(Tue, May 14)
- Q1 2013 Nupathe Inc Earnings Release - Before Market OpenCCBN(Tue, May 14)
- NUPATHE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, May 14)
- 5 Reasons Not to Worry This Weekat Motley Fool(Mon, May 13)
- NuPathe Announces Allowance of Additional U.S. Patent Application for NP201Marketwired(Mon, May 13)
- NuPathe to Host Conference Call to Discuss First Quarter 2013 Results on Tuesday, May 14, 2013Marketwired(Tue, May 7)
- NuPathe Announces Allowance of U.S. Patent Application for NP201Marketwired(Thu, Apr 25)
- 4 Health Care Stocks Under $10 to Watchat TheStreet(Tue, Apr 16)
- 3 Biotechs With Upcoming Product Launchesat Seeking Alpha(Thu, Apr 11)
- A Fool Looks Backat Motley Fool(Sat, Mar 30)
- NUPATHE INC. Files SEC form 10-K, Annual ReportEDGAR Online(Wed, Mar 27)
- NuPathe Management Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Mar 26)
- NuPathe see existing cash funding operations into Q4theflyonthewall.com(Tue, Mar 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.16 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.20 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders.
View More 
0.08%